Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials-Reference-Cited by-同舟云学术

Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials

Published:2013-11-18 Issue:4 Volume:135 Page:763-773
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Santoni Matteo¹,Conti Alessandro²,De Giorgi Ugo³,Iacovelli Roberto⁴,Pantano Francesco⁵,Burattini Luciano¹,Muzzonigro Giovanni²,Berardi Rossana¹,Santini Daniele⁵,Cascinu Stefano¹

Affiliation:

1. Department of Medical Oncology; Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi; Ancona Italy

2. Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche Clinica di Urologia, AOU “Ospedali Riuniti; ” Università Politecnica delle Marche; Ancona Italy

3. IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-IRST; Meldola Italy

4. Dipartimento di Scienze Radiologiche Oncologiche e Anatomo-Patologiche; “Sapienza” Università di Roma; Rome Italy

5. Department of Medical Oncology; University Campus Bio-Medico; Rome Italy

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference36 articles.

1. Anti-angiogenesis: new concept for therapy of solid tumors;Folkman;Ann Surg,1972

2. Mechanisms of adverse effects of anti-VEGF therapy for cancer;Kamba;Br J Cancer,2007

3. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

4. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

5. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma;Escudier;J Clin Oncol,2009

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors;Cancer Management and Research;2023-09

2. Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact;Scientific Reports;2023-08-25

3. Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle;BJC Reports;2023-08-02

4. miR-27a-3p Nanoparticle Alleviate Sunitinib-Induced Cardiotoxicity Through Inhibiting LATS2;Journal of Biomedical Nanotechnology;2023-08-01

5. Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis;Oncology Letters;2023-05-10